CVS Health (CVS) Increases Despite Market Slip: Here's What You Need to Know

CVS Health (CVS) closed at $77.90, up 1.51%, significantly outperforming the S&P 500's 2.71% daily loss. Analysts project strong growth for its upcoming October 29, 2025 earnings report, with expected EPS of $1.36 (+24.77% YoY) and revenue of $98.31 billion (+3.02% YoY), alongside robust full-year estimates. Despite a Zacks Rank of #3 (Hold), CVS trades at a Forward P/E of 12.06 and a PEG ratio of 0.85, indicating a discount relative to its Medical Services industry averages of 17.04 and 1.68, respectively.

Analysis

CVS Health (CVS) demonstrated significant relative strength, closing up 1.51% at $77.90 during a broad market downturn where the S&P 500, Dow, and Nasdaq all experienced substantial daily losses. This outperformance suggests a defensive characteristic, with the stock also appreciating 2.77% over the past month, exceeding the Medical sector's gain.

Analysts anticipate robust growth for CVS's upcoming October 29, 2025, earnings report, projecting a 24.77% year-over-year EPS increase to $1.36 and a 3.02% revenue escalation to $98.31 billion. Fiscal year estimates also remain strong, with EPS expected to grow 17.34% to $6.36 and revenue by 4.91% to $391.11 billion. However, the Zacks Rank is currently #3 (Hold), with consensus EPS projections remaining stagnant over the last 30 days.

Valuation metrics indicate CVS trades at a discount, with a Forward P/E of 12.06 compared to the industry average of 17.04, and a PEG ratio of 0.85 versus the industry's 1.68. This suggests the stock is undervalued relative to its growth prospects. Despite this, the Medical Services industry, to which CVS belongs, carries a Zacks Industry Rank of 157, placing it in the bottom 37% of industries, which historically underperforms.

Key Decisions for Investors

• Monitor the upcoming October 29, 2025, earnings report for CVS Health to confirm projected strong EPS and revenue growth, which could act as a significant catalyst.
• Consider CVS's attractive valuation, evidenced by its discounted Forward P/E and PEG ratios relative to industry averages, especially given its demonstrated market resilience.
• Evaluate the potential impact of the Medical Services industry's lower Zacks Industry Rank, as broader sector underperformance could present headwinds despite strong company fundamentals.
• Track any future analyst estimate revisions for CVS, as positive changes are historically correlated with favorable stock price performance, particularly following the recent stagnation in EPS projections.